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Abstract
Distinguishing between clastogens and aneugens is vital in cancer risk assessment because the default assumption is that
clastogens and aneugens have linear and non-linear dose-response curves, respectively. Any observed non-linearity must be
supported by mode of action (MOA) analyses where biological mechanisms are linked with dose-response evaluations. For
aneugens, the MOA has been well characterised as disruptors of mitotic machinery where chromosome loss via micronuclei
(MN) formation is an accepted endpoint used in risk assessment. In this study we performed the cytokinesis-block
micronucleus assay and immunofluorescence mitotic machinery visualisation in human lymphoblastoid (AHH-1) and
Chinese Hamster fibroblast (V79) cell lines after treatment with the aneugen 17-b-oestradiol (E2). Results were compared to
previously published data on bisphenol-A (BPA) and Rotenone data. Two concentration-response approaches (the
threshold-[Td] and benchmark-dose [BMD] approaches) were applied to derive a point of departure (POD) for in vitro MN
induction. BMDs were also derived from the most sensitive carcinogenic endpoint. Ranking comparisons of the PODs from
the in vitro MN and the carcinogenicity studies demonstrated a link between these two endpoints for BPA, E2 and
Rotenone. This analysis was extended to include 5 additional aneugens, 5 clastogens and 3 mutagens and further
concentration and dose-response correlations were observed between PODs from the in vitro MN and carcinogenicity. This
approach is promising and may be further extended to other genotoxic carcinogens, where MOA and quantitative
information from the in vitro MN studies could be used in a quantitative manner to further inform cancer risk assessment.
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Introduction
Cancer risk assessment is based on low-dose extrapolation of the
risk of chemical carcinogens based on their mode of action
(MOA). Genotoxic carcinogens, which are clearly DNA reactive
and initiating, follow a linear approach for risk assessment, while
indirect and non-DNA reactive carcinogens such as aneugens, and
topoisomerase poisons follow a non-linear or threshold approach
[1,2]. Thus establishing the MOA of substances is important for
deciding which approach to use for risk characterization.
Aneugens are agents which affect cell division and the mitotic
spindle apparatus resulting in the loss or gain of whole
chromosomes, in comparison to clastogens which are agents that
induce breaks in chromosomes leading to sections of the
chromosomes being added, deleted or rearranged, or mutagens
which are agents which induce mutations. Aneugens were the first
class of genotoxic compounds to have well established non-linear
dose-responses [3,4] and the underlying mechanisms responsible
for these thresholds are important for hazard and risk assessment.
Therefore, distinguishing between aneugens and other genotoxic
compounds such as clastogens and mutagens has important
implications in cancer risk assessment.
Genotoxicity tests are often used to determine the mutagenic
potential of substances because the accumulation of mutations is
essential for tumour development, albeit in a qualitative manner.
Efforts are presently being made to compare data from in vitro and
in vivo genotoxicity tests and carcinogenicity studies to determine if
a quantitative relationship between these two endpoints exists. The
main goal here is to investigate whether in vitro or in vivo
genotoxicity tests can provide carcinogenic potency information
and whether the concentration-response curves can provide
information on genotoxic MOA (linear versus non-linear concen-
tration/dose-response curves observed for clastogens and aneu-
gens, respectively). A recent study showed a correlation between
the in vivo MN and carcinogenicity for numerous carcinogens with
different MOAs [5], and this approach was of interest for the
current work. This quantitative framework has gained interna-
tional interest, particularly with the International Life Science
Institute (ILSI) Health and Environmental Sciences Institutes
(HESI) in vitro genotoxicity testing (IVGT, renamed Genetic
Toxicology Technical Committee (GTTC) in 2012) quantitative
subgroup which has led to the implementation of different
concentration- and dose-response modelling approaches for
different compounds [6]. The main objective being to put more
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emphasis on genetic toxicity data to reduce follow up animal
testing and to see if the in vitro data can be used in a quantitative
fashion [7]. Most of the work to date has focused primarily on
DNA reactive genotoxic compounds. Our work is novel in that we
aim to apply the various concentration-response approaches on
the well-characterised aneugens 17-b-oestradiol (E2), bisphenol-A
(BPA) and Rotenone.
Several methods are currently available for testing the genotoxic
potential of chemicals in vitro. The cytokinesis-block micronucleus
(CBMN) assay is an accepted test for determining the genotoxic
potential of a substance [8–11]. Micronuclei (MN) can be formed
in dividing cells that either contain chromosome breaks lacking
centromeres or whole chromosomes that are unable to travel to
the spindle poles during mitosis [12,13]. The CBMN assay is a
convenient and reliable test for the measurement of both
chromosome breakage as induced by clastogens and chromosome
loss as induced by aneugens. The term aberrant mitotic machinery
is defined as the disruption of the microtubules and centrosomes.
This can occur by multiple centrosomes being induced by these
spindle poisons, resulting in tri, tetra and multi-polar cells,
compared to the normal bipolar mitotic cells. Therefore, by
visualising the mitotic machinery using immunofluorescence to
target a or b-tubulin (microtubules), c-tubulin (centrosomes) and
DNA by using 4’,6-diamidino-2-phenylindole (DAPI), possible
MOA for aneugens can be determined. This information can be
visualised at concentrations surrounding the no-observed effect
level (NOEL) for MN induction to obtain a possible MOA for
aneuploidy [14,15]. Here, we put forth an alternative method to
the commonly used fluorescence in situ hybridization (FISH) for
discriminating between aneugens and clastogens.
In this study we performed the CBMN assay and immunoflu-
orescence mitotic machinery visualisation (IMMV) in the human
lymphoblastoid cell line (AHH-1) and the Chinese Hamster
fibroblast cell line V79 (V79) exposed to various concentrations of
E2. Results from E2 were compared to previously published data
for BPA and Rotenone [14]. Different concentration-response
analyses were performed including the threshold-dose (Td) and the
benchmark-dose (BMD) approach to determine a POD for in vitro
MN induction alongside MOA analysis via IMMV. BMD analysis
was also performed for carcinogenicity studies to determine an
in vivo POD. The lowest in vitro MN POD was compared to the
lowest in vivo carcinogenicity POD to investigate whether compa-
rable rankings were observed. This analysis was extended to
include 5 additional aneugens (nocodazole, colchicine, mebenda-
zole, carbendazim, and diethylstilbestrol (DES)), 5 clastogens
(bleomycin, thiabendazole, chlorambucil, melphalan, and ure-
thane) and 3 mutagens (cytosine arabinoside, 5-fluorouracil and
methylmethane sulfonate (MMS)) to see if similar trends were
observed between the lowest POD and concentration-response
characteristics from the in vitro MN assay and in vivo carcinoge-
nicity studies.
Materials and Methods
Chemicals
All chemicals including cytochalasin-B (CAS number: 14930-
962) were purchased from Sigma-Aldrich (Poole, UK) unless
otherwise stated. DPX was purchased from Fisher Scientific
(Loughborough, UK). Phosphate Buffer Saline (PBS) was prepared
using tablets purchased from Sigma, which were dissolved in 1 litre
of deionised H20. PBT was prepared using PBS +0.1% Tween 20
(CAS number: 9005-66-7). 17-b-oestradiol (E2, CAS number: 50-
28-2) was dissolved in dimethylsulphoxide (CAS number: 67-68-5,
DMSO).
Cell Lines
The human lymphoblastoid cell line AHH-1 was obtained from
ATCC (CRL-8146, USA, http://www.lgcstandards-atcc.org/
Figure 1. Acridine orange stained AHH-1 cells. (a) Binucleate and
(b) binucleate cell with micronucleus, BN-MN.
doi:10.1371/journal.pone.0064532.g001
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Products/All/CRL-8146.aspx) while the Chinese Hamster fibro-
blast cell line V79 was obtained from European Collection of Cell
Cultures (ECACC, 86041102, HPA, UK) (http://www.
hpacultures.org.uk/products/celllines/generalcell/detail.
jsp?refId = 86041102&collection = ecacc_gc).
In vitro Cytokinesis Blocked Micronucleus (CBMN) Assay
for E2 (Figure 1)
The in vitro CBMN assay in human lymphoblastoid cell line
AHH-1 or the Chinese Hamster fibroblast cell line V79 was used
to detect both structural and numerical chromosome damage by
measuring the formation of MN in interphase cells that have been
through a mitotic division [12]. Examples of binucleate cells (BN)
with and without MN are shown in Figure 1. In order to
determine the effects of E2 upon MN induction and chromosome
segregation, actively growing cell cultures were exposed to graded
concentrations of E2 dissolved in DMSO. AHH-1 cells were grown
in RPMI 1640 medium (Gibco-Invitrogen, Paisley, UK), 10%
horse serum (Gibco-Invitrogen, Paisley, UK) and 1% L-glutamine
(Gibco-Invitrogen, Paisley, UK). Cultures were exposed for a
complete cell cycle (22 to 26 hours dependent upon any cell cycle
delay) in the presence of 3 mg/ml of the actin-inhibitor cytocha-
lasin-B. Cells were washed and centrifuged. Suspensions were then
deposited on slides using a cytocentrifuge. This treatment resulted
in the production of binucleate cells from those cells that have
undergone cell division in the presence of the test chemical and
cytochalasin-B. Slides were fixed with methanol and stained with
either Giemsa (CAS number: 51811-82-6) or acridine orange
(CAS number: 10127-02-3) to detect MN. MN for both control
and treated cultures were scored according to previously
established criteria [12,16].
Aberrant Mitosis Assay: Multiple Centrosomes Induced
by E2
Sterile glass microscope slides were placed in Petri dishes on
which V79 cells were seeded at approximately 7.56104 cells/ml
and grown overnight in fresh medium consisting of Dulbecco’s
Modified Eagles Medium (DMEM) without phenol red (Gibco-
Invitrogen, Paisley, UK), and supplemented with 10% foetal
bovine serum (FBS) (Gibco-Invitrogen, Paisley, UK).Cells were
then incubated for 20 hours in the presence of the E2 dissolved in
DMSO. Colchicine (COL) (CAS number: 64-86-8) was used as a
positive control. The highest concentration of E2 used did not
exceed 50% induced cell toxicity consistent with the OECD
guideline (2010) [11].
Conventional Spindle Staining for E2 (Figure 2)
The cells were washed in PBS and then fixed in 3:1 methanol:
acetic acid (CAS number: 64-19-7) (3614 minutes). Slides were
air-dried and then placed in 5% perchloric acid (7601-90-3) at 4uC
overnight. 0.5% Brilliant blue (CAS number: 6104-59-4, BB) and
0.5% safranin O (CAS number: 477-73-6, SO) in 15% v/v acetic
acid (CAS number: 64-19-7) was added to the slides after washing
106 in distilled water. Slides were air-dried and mounted using
DPX (Fisher, Loughborough, UK).
Immunofluorescence Mitotic Machinery Visualisation
(IMMV) for E2 (Figure 3)
Cells were washed once in ice-cold PBS, and then fixed for 30
minutes in 90% methanol (CAS number: 67-56-1). Slides were
then air dried and stored at 220uC. Frozen slides were placed in
90% methanol at 220uC for 20 minutes and then for 20 s in
acetone (CAS number: 67-64-1) at 220uC. Following PBT
Figure 2. Microtubule staining of normal V79 cells, (a)
metaphase and (b) interphase, and an example of a spindle
aberration induced by E2 in V79 cell, (c) tripolar metaphase. a-
Tubulin stains, green=microtubules; c-tubulin stains, orange= centro-
somes; DAPI, blue = chromosomes.
doi:10.1371/journal.pone.0064532.g002
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rinsing, cells were incubated for 2 hours in a humidified chamber
at 37uC with a diluted mouse anti c-tubulin antibody (diluted
1:200 with PBS) (Sigma, Poole, UK). Then slides were rinsed with
PBT and incubated for 2 h at 37uC in a humid chamber with
TRITC-conjugated secondary anti-mouse antibody (diluted 1:32
with PBS). After extensive washing in PBT, cells were kept for 1 h
in the presence of a mouse monoclonal anti-a-tubulin conjugate
clone (diluted 1:100 with PBS). DNA was counterstained with
DAPI [17,18].
BPA and Rotenone
We have previously characterised the MOA of BPA by
employing kinetochore staining [15,18] which shows if the MN
contains a chromosome fragment (i.e. compound is clastogenic), or
a whole chromosome (i.e. compound is aneugenic) [11,18]. In
addition, a summary of NOELs and/or LOELs from genetic
toxicity tests after treatment with BPA is illustrated in Table 1.
In vitro MN Analysis of Other Genotoxic Compounds
An analysis was performed of the literature in search for in vitro
MN data from different human lymphocyte cell line studies, in
addition to the E2, BPA and Rotenone derived by Johnson and
Parry (2008) [14]. In vitro MN data on human lymphocytes
exposed to aneugens nocodazole, colchicine, mebendazole, and
carbendazim, and the alkylating agent MMS were derived from
Elhajouji et al. (1997) [3]. In vitro MN data on human lymphocytes
exposed to aneugens colchicine and DES, the nucleoside
analogues cytosine arabinoside and 5-fluorouracil, and the
clastogens bleomycin, urethane and thiabendazole were derived
from Clare et al. (2006) [19]. In vitro MN data on human
lymphocytes exposed to clastogens chlorambucil and melphalan
were derived from Efthimiou et al. (2007) [20].
Derivation of in vitro POD from MN Studies
Threshold dose approach. In vitro MN concentration-
response analysis was performed from the data generated in this
study for E2, and for BPA and Rotenone data derived from
Figure 3. Immunofluorescence mitotic machinery visualisation (IMMV) of normal bipolar V79 cells. (a) Metaphase, (b) telophase and (c)
interphase. Examples of spindle aberrations induced by E2 in V79 cell, (d) Tripolar metaphase and (e) multipolar metaphase. a-Tubulin stains,
green=microtubules; c-tubulin stains, orange= centrosomes; DAPI, blue = chromosomes.
doi:10.1371/journal.pone.0064532.g003
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Johnson and Parry (2008) [14]. Two methods were used for
concentration-response analysis: Td and BMD. Threshold mod-
elling used a similar approach to Gocke and Wall (2009) [21] and
Johnson et al., 2009 [22]. This was performed using a 4 step
approach. Briefly, Step 1 involved a one-way ANOVA for a dose-
related effect (SPSS version 16.0.1). Step 2 involved a comparison
of linear and quadratic models using the coefficient of determi-
nation (R2, SPSS version 16.0.1). The F distribution was then used
to calculate P values in Microsoft Excel 2007. Step 3 involved the
determination of no-observed-genotoxic-effect level (NOGEL) or
lowest-observed-genotoxic-effect-level (LOGEL) values using a
one-sided Dunnett’s test on either untransformed or log-trans-
formed data (SPSS version 16.0.1). Linear and quadratic models
were then compared at the NOGEL and below in the same way as
Table 1. Summary of NOELs and/or LOELs from genetic toxicity tests after treatment with BPA [28–34].
End Point Cell Line NOEL LOEL Reference
In vitro
Chromosome aberrations SHE 200 mM/46 mg/ml Tsutsui 1998
DNA adducts SHE 50 mM/11.5 mg/ml Tsutsui 1998
DNA adducts Rat liver 100 mM/23 mg/ml Atkinson and Roy 1995
Chromosome aberrations CHO 350 mM/80.5 mg/ml 400 mM/92 mg/ml Hilliard 1998
Chromosome aberrations CHO 220 mM/50 mg/ml Ivett 1989
SCE CHO 130 mM/30 mg/ml Ivett 1989
Aberrant spindles V79 100 mM/23 mg/ml Ochi 1999
c-tubulin V79 100 mM/23 mg/ml Ochi 1999
Multipolar division V79 100 mM/23 mg/ml Ochi 1999
Microtubule Bovine-MT 50 mM/11.5 mg/ml 100 mM/23 mg/ml Pfeiffer 1997
CMTC V79 200 mM/46 mg/ml Pfeiffer 1997
Metaphase arrest V79 50 mM/11.5 mg/ml 100 mM/23 mg/ml Pfeiffer 1997
Micronuclei V79 100 mM/23 mg/ml Pfeiffer 1997
In vivo
DNA adducts Rat 200 mg/kg Atkinson and Roy 1995
NOEL, No-observed effect level; LOEL, lowest-observed effect level; SHE = Syrian Hamster Embryo; SCE, sister chromatid exchange; CHO=Chinese Hamster Ovary;
V79 = Chinese Hamster fibroblast cell line; CMTC, cytoplasmic microtubule complex.
doi:10.1371/journal.pone.0064532.t001
Table 2. Analysis of carcinogenicity data from the National Toxicology Program (http://ntp.niehs.nih.gov/).
Compound Sex Tissue BMD10 (mg/kg/day) BMDL10 (mg/kg/day) BMDU10 (mg/kg/day)
DES F Pituitary gland adenoma 0.001 0.0005 0.0024
DES F Cervix squamous cell carcinoma 0.07 0.05 0.12
DES M Testes interstitial cell tumor 0.017 0.014 0.02
DES M Pituitary gland adenoma 0.003 0.002 0.005
DES F Pituitary gland adenoma 0.039 0.03 0.06
DES F Cervix squamous cell carcinoma 0.029 0.02 0.04
DES F Mammary gland adenocarcinoma, Type B 0.032 0.011 0.091
DES F Cervix adenoacanthoma 0.086 0.06 0.13
DES M Testis interstitial cell tumor 0.0066 0.004 0.008
DES F Mammary gland carcinoma 0.0003 0.00003 0.0014
DES F Pituitary gland adenoma 0.0009 0.0004 0.0019
DES M Testis interstitial cell tumor 0.0094 0.007 0.012
DES F Pituitary gland adenoma 0.0007 0.0004 0.0014
E2 F Mammary gland adenocarcinoma 0.56 0.28 2.02
BPA F+M Leukemia 42.8 25.99 114.9
BPA M Leukemia 38.5 20.94 201.7
BPA F Leukemia 56.5 N/A N/A
Rotenone M Parathyroid glad adenoma N/A N/A N/A
doi:10.1371/journal.pone.0064532.t002
Mode of Action Approach for Carcinogens
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64532
described in Step 2. Data that had a flat or zero dose-response
slope at the NOGEL and below were then suitable for bilinear or
hockey stick analysis. Step 4 involved a comparison of linear versus
hockey stick models using the R software package (version 12.2)
recommended by Lutz and Lutz (2009) [23]. Parameters, y-
intercept, Td, and slope above Td were estimated for best fit of a
hockey stick model by minimizing the residual sum of squares.
Confidence intervals (CI) were estimated for all parameters using
an F distribution [23]. If the 95% CI of the derived Td value does
not encompass zero, the model is considered a good fit to the data.
Benchmark dose approach. The BMD approach was
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Figure 4. Using the CBMN to assess % binucleate cells with MN
(%BN-MN) and cell cytotoxicity and/or cytostasis (% Cell
Viability) in AHH-1 cells after E2 treatment at super-physio-
logical concentrations. 361,000 binucleate cells were examined for
the presence of BN-MN. Cell viability (%) was calculated from the
cytokinesis-block proliferation index (CBPI) measure (OECD, 2010) by
scoring approximately 8,000 cells per dose. 0.8 mM E2 and above were
significant to p,0.05 for BN-MN, by comparison to the control using
Dunnett’s.
doi:10.1371/journal.pone.0064532.g004
Figure 5. Using the Aberrant Mitosis Assay to show the activity
of 17-b-oestradiol (E2) as a spindle poison, and to give the
concentration-response relationship at super-physiological
concentrations. Tripolar (Tri) was calculated using number of tripolar
cells compared to number of mitotic cells (36100 in total) using IMMV.
Mitotic Index (MI) was calculated using number of mitotic cells
compared to number of interphase cells (361,000 cells in total) using
conventional spindle staining. 0.8 mM E2 and above were significant to
p,0.05 for both MI and Tri, by comparing to the control using
Dunnett’s.
doi:10.1371/journal.pone.0064532.g005
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performed using the statistical package PROAST [24] to derive
BMC10 (in vitro) and BMD10 (in vivo) values for each data set with a
benchmark response of 10% as previously done for in vivo and
in vitro genotoxicity data [25]. The BMD approach estimates a
dose (i.e., the BMD or BMC) that produces some predetermined,
and presumably biologically relevant, increase in the response over
control (i.e., the benchmark response). The approach employs
mathematical dose–response modeling that takes factors such as
sample size and shape of the curve into account [26]. BMC10 and
BMD10 values were derived using the dose-response modeling
software package PROAST, developed at the National Institute
for Public Health and the Environment (RIVM) in the Nether-
lands (www.proast.nl). The models used were the exponential
models recommended by the European Food Safety Authority
[27]. Model selection was performed using the log-likelihood ratio
test that assesses whether a statistically significant improvement in
the fit is achieved by adding additional parameters. The model
with additional parameters is only accepted if the difference in log-
likelihoods exceeds the critical value at P=0.05. This is
automatically performed in PROAST by selecting the ‘‘automatic
selection of optimal model from nested family’’ option. A log-
likelihood value is also provided for the ‘‘full’’ model, which is
simply the set of the geometric means of the observations at each
dose (together with the residual variance). The log-likelihood ratio
test can be used to compare the selected model with the full model
using a goodness-of-fit test. The model is accepted when the log-
likelihood value of the fitted model is significantly better than that
of the full model. The BMC10 and BMD10 with their associated
lower (BMDL) confidence limits were then derived from the
selected model. Therefore, a BMDL10 refers to the estimate of
lower 95% CI of a dose that produces a 10% increase over the
fitted background level for continuous endpoints, and 10% extra
risk for quantal endpoints.
Derivation of in vivo POD for Carcinogenicity
Carcinogenicity data were taken from the National Toxicology
Program (NTP) and Carcinogenic Potency Databases (CPD). The
BMD approach was used to derive a dose that increases the tumor
response by 10% over the modelled control (BMD10), with its
respective upper (BMDU10) and lower (BMDL10) confidence limit
(Table 2). The lowest confidence limit of the BMD10 (BMDL10)
from the most sensitive tumor endpoint was selected as the POD
for carcinogenicity data.
Results
17-b-oestradiol (E2)
Aneugenicity, cytotoxicity and cytostasis testing of E2 was
conducted in AHH-1 cells using the CBMN assay and the
aberrant mitosis assay. These endpoints were chosen to observe
the genotoxic effects of E2 and give a greater understanding of the
MOA. E2 was found to induce MN at super-physiological levels of
E2 (0.8–1.0 mM) with a significant decrease in cell viability
(p,0.05) at the same concentrations (Figure 4). The td-L-CI for
MN induction was observed at 0.74 mM and for effects on spindle
formation (Tripolar) at 0.45 mM (Table 3). The first significant
(p,0.05) increase (LOEL) for MN induction and for effects on
Figure 6. Mammalian cells treated with 17-b-oestradiol (E2)
treated mammalian cells with the following endpoints. (a) MN
(AHH-1), (b) MI (V79) and (c) Tripolar (V79). Graphs shown are from the
Lutz and Lutz (2009, [23]) hockey stick model for R, with the dotted line
being the lower 95% confidence interval. The x-axis ‘dose’ is in mM, and
y-axis ‘response’ is % cells.
doi:10.1371/journal.pone.0064532.g006
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spindle formation (Tripolar) was observed at 0.8 mM. The BMD
approach showed a BMCL10 of 0.40 and 0.02 mM for MN and
spindle formation induction, respectively (Table 3). If there was a
decrease of 50% cell viability or less at a genotoxic (i.e. clastogenic)
effect, then the MOA was said to potentially be a cytotoxicity
related secondary mechanism and not a true genotoxic response
[11]. However, there was only a decrease of 10%–20%
cytotoxicity and/or cytostasis when a 2–36 fold increase in MN
is observed, which indicated that E2 was genotoxic through a non-
cytotoxicity related MOA. The NOEL was defined as the lowest
value produced between the Td-L-CI and BMCL10 in both the
chromosome loss (MN) and spindle formation effects. This was
justified because non-disjunction is known to occur at lower
concentrations than chromosome loss ([4](Table 3). With this
criterion, the NOEL for E2 was 0.02 mM. The most sensitive
carcinogenicity endpoint with the lowest BMDL10 was observed in
the mammary gland with a BMDL10 of 0.28 mg/kg/day
(1.03 mM/day; Tables 2 and 3).
Discussion
The goal of this analysis was to investigate whether carcinogenic
potency information (i.e. cancer potency ranking) could be derived
from in vitro MN data. For this, several quantitative dose-response
methods were investigated for the selection of a suitable in vitro
MN POD for BPA, E2, and Rotenone. In order to investigate
which method was more appropriate for POD derivation, the
traditional method for analysing in vitro genotoxicity data (i.e.
derivation of no-observed-effect-level (NOEL) or a lowest-
observed-effect-level (LOEL)) was compared to more recent
quantitative methods. First, a summary of BPAs effects in different
genetic toxicology tests is represented in Table 1. From Table 1, it
was clear that the NOELs vary significantly between the different
Figure 7. Mammalian cells treated with bisphenol-a (BPA) using the following endpoints. (a) MN (AHH-1), (b) MI (V79) and (c) Tripolar
(V79), and (d) multi+tetrapolar (V79). Graphs shown are from the Lutz and Lutz (2009, [23]) hockey stick model for R, with the dotted line being the
lower 95% confidence interval. The x-axis ‘dose’ is in mM, and y-axis ‘response’ is % cells.
doi:10.1371/journal.pone.0064532.g007
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Figure 8. BMD analysis of studies by Johnson and Parry (2008, [14]) for (a) E2, (b) BPA and (c) Rotenone; by Elhajouji et al. (1997,
[3]) (d) nocodazole, (e) colchicine, (f) mebendazole, (g) carbendazim, and (h) MMS; by Clare et al. (2006 [19]) for (i) colchicine, (j)
DES, (k) cytosine arabinoside, (l), 5-fluorouracil, (m) bleomycin (n) urethane, and (o) thiabendazole; and by Efthimiou et al. (2007,
[20]) for (p) chlorambucil and (q) melphalan.
doi:10.1371/journal.pone.0064532.g008
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in vitro genotoxic endpoint ranging from 25 to 250 mM. The
NOEL or LOEL are not the ideal method for performing
concentration-response analysis. Comparison of the NOELs from
chromosomal aberrations in Chinese Hamster Ovary (CHO) cells
between Hilliard et al. (1998) [28]350 mM and Ivett et al. 1989 [29]
220 mM clearly demonstrates how deriving the NOEL using the
traditional method is highly dependent on experimental condi-
tions. In addition, NOEL only used one concentration and not the
entire data set, and no confidence limits can be derived. In
contrast, quantitative methods such as the Td and BMD approach
use all the data, are not so dependent on experimental conditions
and provide confidence limits [26]. For this reason, the Td and
BMD approach were selected for the derivation of POD from
in vitro MN studies. The lowest reported NOEL observed was
50 mM or 11.5 mg/ml for metaphase arrest in the V79 cell line
(Table 1) [30]. For the current study in which we carried out
extensive statistical modelling on our previously published BPA
data [14], the td-L-CI for MN-induction and disruption in spindle
formation was observed at 2.58 and 15.42 mM, respectively
(Table 3). Similarly, BMCL10 were 5.48 and 3.13 for MN and
spindle effects, respectively. Therefore, the POD for in vitro MN
for BPA was 2.58 mM.
E2 and BPA (xenoestrogens) are spindle poisons with well-
characterised thresholds for genotoxic activity [3,4], while no
concentration-response was observed with Rotenone (Table 3). E2
and BPA showed clear thresholds for MN, mitotic index (MI) and
tripolarity. This is to be expected as hormones are presumed to
have non-linear concentration and dose-responses [1], and this
study confirms these observations (Figures 4–7). In addition,
comparisons of PODs between in vitro MN and carcinogenicity
were made. Table 3 demonstrated that the BMCL10s for in vitro
MN were ranked as E2.BPA..Rotenone. The carcinogenicity
ranking of the most sensitive tumour endpoint (Table 2) was also
E2.BPA..Rotenone (Table 3). These results, although with
limited number of compounds, were very promising indicating the
potential for deriving carcinogenic potency information from
in vitro MN studies.
Given the promising ranking results observed with E2, BPA and
Rotenone, we extended our analysis and performed a literature
search for in vitro MN data in human lymphocytes [3,14,19,20].
With this analysis we wanted to explore the applicability of using
concentration-response analysis to extrapolate information in
regards to linear versus non-linear concentration-responses and
carcinogenic potency. Based on the concentration-response curves
in Figures 8a–q, a clear distinction in the shape of the
concentration-response curves from in vitro MN for aneugens
(Figure 8: a, E2; b, BPA; c, Rotenone; d, nocodazole; e, colchicine;
f, mebendazole; g, carbendazim; i, colchicine; and j, DES) and
clastogens (Figure 8: m, bleomycin; p, chlorambucil; and q,
melphalan). The in vitro MN concentration dose-response curves
were clearly non-linear for aneugens and linear from clastogens.
Substances which were more mutagenic than clastogenic and
require metabolic activation such as urethane (Figure 8 n) showed
no concentration-response. The concentration-response curves
from the in vitro MN from mutagenic substances such as methyl
methanse sulfonate (MMS; Figure 8 h) and cytosine arabinoside
Table 4. Summary of BMDL10s derived from different human lymphocyte and AHH-1 cell line studies [3,14,19,20].
Compound Classification
CP, Most sensitive tissue/
endpoint
CP,
BMDL10
(mM/day)
In vitro,
BMCL10 (mM)
MN (%MN) In vitro cell line Reference
E2 aneugen mammary gland
adenocarcinoma
1.03 0.40 AHH-1 cell line Johnson and Parry (2008)
BPA aneugen leukemia 91.73 5.48 AHH-1 cell line Johnson and Parry (2008)
Rotenone aneugen parathyroid gland adenoma? no DR no CR AHH-1 cell line Johnson and Parry (2008)
Nocodazole aneugen N/A N/A 0.0026 human lymphocytes Elhajouji et al. (1997)
Colchicine aneugen promoter in two-stage skin
tumor model
N/A 0.004 human lymphocytes Elhajouji et al. (1997)
Mebendazole aneugen N/A N/A 0.107 human lymphocytes Elhajouji et al. (1997)
Carbendazim aneugen hepatocellular adenomas and
carcinomas
62.08 0.26 human lymphocytes Elhajouji et al. (1997)
MMS alkylating agent N/A N/A 7.51 human lymphocytes Elhajouji et al. (1997)
Colchicine aneugen N/A N/A 0.005 human lymphocytes Clare et al. (2006)
DES aneugen mammary gland carcinoma 0.0001 6.90 human lymphocytes Clare et al. (2006)
Cytosine
arabinoside
nucleoside analogue N/A N/A 0.53 human lymphocytes Clare et al. (2006)
5-Fluorouracil nucleoside analogue lung and lymphoreticular
system
22.76 48.20 human lymphocytes Clare et al. (2006)
Bleomycin clastogen N/A N/A 0.0002 human lymphocytes Clare et al. (2006)
Urethane clastogen (requires
metabolic activation)
lung alveolar-bronchiolar
adenoma
0.11 no CR human lymphocytes Clare et al. (2006)
Thiabendazole clastogen no positive in CPD no DR no CR human lymphocytes Clare et al. (2006)
Chlorambucil clastogen Lymphosarcoma 0.0007 0.006 human lymphocytes Efthimiou et al. (2007)
Melphalan clastogen tumor-bearing animals mixed 0.013 0.002 human lymphocytes Efthimiou et al. (2007)
CP, carcinogenic potency was derived from studies carcinogenic potency database (www.berkley.org) and National Toxicology Program (NTP); POD, point of departure;
MI, mitotic index; MN, frequency of micronuclei formation, DR, dose-response; CR, concentration response.
doi:10.1371/journal.pone.0064532.t004
Mode of Action Approach for Carcinogens
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e64532
(Figure 8 k) seemed to have non-linear concentration-response
curves. This has been previosly demonstrated for MMS [25] but
more research on the MOA of cytosine arabinoside is needed to
verify our observation. Other genotoxic substances such as 5-
fluorouracil (Figure 8 l) had concentration-response curves which
were clearly linear at the concentrations tested. Thus, similar
concentration-response curves could be used to group substances
in terms of their genotoxic MOA and further obtain potency
information.
In terms of carcinogenic potency, it was very difficult to make
any inferences given the limited in vitro MN and carcinogenicity
data (Figure 8 a–q). For the study of Elhajouji et al. (1997) [3], only
carbendazim had carcinogenicity data. The study by Clare et al.
(2006) [19] showed a carcinogenicity ranking of BMDL10a of
DES.urethane.5-fluorouracil. The BMCL10s from in vitro MN
showed a genotoxicity ranking of bleomycin.colchicine.cytosine
arabinoside.DES.5-fluorouracil (Table 4). For compounds
which had both MN and carcinogenicity data, the rankings did
not differ significantly, with the exception of urethane which
requires metabolic activation and had no concentration-response.
For the study by Efthimiou et al. (2007) [20], the carcinogenicity
ranking was chlorambucil.melphalan while the genotoxicity
ranking was melphalan.chlorambucil. No true conclusions can
be made until more substances are tested. To the best of our
knowledge, this is the firt study to try to attempt to investigate
whether carcinogenic potency information can be derived from
in vitro MN studies in human lymphocytes using quantitative
approaches. Atlhough inconclusive, these results were promising
and more in vitroMN studies under the same conditions (treatment
schedule and recovery) and carcinogenicity studies are needed.
Conclusions
Here we demonstrated that combining the micronucleus assay
along with aberrant mitotic analysis in AHH-1 and V79 cells, has
risk assessment applications for the identification of aneugens, and
the derivation of PODs using Td and BMD statistical modelling
approaches. The traditional NOEL method for deriving POD is
less suitable for analyzing in vitro genotoxicity data and quantita-
tive approaches such as the Td and BMD are recommended for
future POD derivation. The concentration-response curves from
the in vitro MN in AHH-1 and human lymphocytes provide useful
information on linear versus non-linear concentration-response
which has risk assessment implications. Comparison of POD
ranking between the in vitro MN and carcinogenicity were
comparable with E2, BPA and Rotenone but comparisons with
other clastogens and mutagens were inconclusive.
Further analysis is needed to investigate whether POD
derivation from in vitro MN studies may provide carcinogenic
potency information.
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